Key result
Twice-daily dosing, younger age, and male sex predict ~7% one-year DOAC nonadherence in AF patients.
Cohort (n=46,211)
Yes
One-year nonadherence to DOACs in newly treated AF patients is relatively low (6.5%), but younger age, male sex, and twice-daily dosing regimens are significant predictors of nonadherence.
Nonadherence predictors in AF on DOACs warrant monitoring in at-risk groups; hypothesis-generating and leaves open whether interventions improve outcomes.
One-year nonadherence to DOACs was low yet relevant in patients with AF newly prescribed a DOAC. Understanding the predictors for nonadherence may help identify patients at risk.
No takes yet. Share an insight, caveat, or question.
Horst et al. (2023) conducted a cohort in Atrial Fibrillation (n=46,211). Direct Oral Anticoagulants (DOACs) was evaluated on 1-year nonadherence (PDC < 80%). In patients with atrial fibrillation newly prescribed a DOAC for at least 1 year, the prevalence of 1-year nonadherence was 6.5%, with male sex, younger age, and twice-daily dosing as predictors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: